Pharma Journalist -

Curis, Inc. announced that it has entered into an option and license agreement to acquire exclusive, worldwide rights from ImmuNext Inc. (ImmuNext) to develop and commercialize…
Read More...

AstraZeneca announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce…
Read More...

Merck, known as MSD outside the United States and Canada, announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., (“Taiho”) and…
Read More...

Bicycle Therapeutics plc announced a second collaboration with Cancer Research UK in which Cancer Research UK will fund and sponsor development of BT7401, a multivalent Bicycle CD137…
Read More...

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA ("saRNA")…
Read More...

Veristat, a full-service CRO, announced that it has completed the acquisition of The Clinical Trial Company Ltd. (TCTC Group), a global Contract Research Organization headquartered in…
Read More...

SMi Reports: The Injectable Drug Delivery Conference returns to London on 13th and 14th May, 2020 SMi Group is delighted to announce the highly anticipated 3rd annual Injectable Drug…
Read More...

InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced that the company has…
Read More...

ATAI Life Sciences AG announced that it has partnered with Neuronasal Inc., to develop a short-term treatment for mild Traumatic Brain Injury (mTBI) or concussion. Neuronasal's…
Read More...

Pulmatrix, Inc. a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced that it has entered into a research…
Read More...